Lead Plaintiff Deadline: June 06, 2022
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
In order to be included in the lawsuit, you must have incurred a loss on shares of AbbVie purchased or acquired during the class period listed above.
If you suffered a loss in AbbVie during the relevant time frame, you have until June 06, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.